There are 2789 resources available
283P - Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: ePoster Display
284P - Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
Presenter: Seock-Ah Im
Session: ePoster Display
285P - Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
Presenter: Li Hao
Session: ePoster Display
286P - Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Presenter: Cecile Bigot
Session: ePoster Display
287P - Burden of illness of HER2+ in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)
Presenter: Gerard Vondeling
Session: ePoster Display
288P - Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
Presenter: Ting Luo
Session: ePoster Display
289P - A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1
Presenter: Asbjørn Due
Session: ePoster Display
290P - Treatment with tyrosine kinase inhibitors (TKIs) based therapy in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study
Presenter: Yijia Hua
Session: ePoster Display
291P - HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
Presenter: Jean-Sebastien Frenel
Session: ePoster Display